-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

835 Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820

Program: Oral and Poster Abstracts
Type: Oral
Session: 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Treatment of BCR:ABL+ and T Cell Diseases
Hematology Disease Topics & Pathways:
Research, Combination therapy, Translational Research, Treatment Considerations, Adverse Events, Measurable Residual Disease
Monday, December 9, 2024: 2:45 PM

Sabina Chiaretti, MD, PhD1, Matteo Leoncin2*, Loredana Elia1*, Stefano Soddu3*, Alfonso Piciocchi3*, Mabel Matarazzo4*, Mariangela Di Trani4*, Maurizio Martelli, MD1*, Erika Borlenghi, MD5*, Marina Parisi6*, Valentina Mancini, MD7*, Caterina Alati, MD8*, Daniele G. Mattei, MD9, Maria Paola Martelli, MD, PhD10*, Prassede Salutari, MD11*, Patrizia Chiusolo, MD, PhD12*, Ernesta Audisio, MD13*, Mario Luppi, MD14*, Lara Pochintesta15*, Crescenza Pasciolla16*, Bianca Serio, MD17*, Barbara Scappini18*, Antonella Cucca19*, Martina Chiarucci20*, Massimiliano Bonifacio, MD21*, Nicola Fracchiolla22*, Silvia Imbergamo23*, Lucia Ammirati, MD24*, Federico Mosna25*, Patrizia Zappasodi26*, Sara Mastaglio, MD27*, Daniela Pietrasanta28*, Monica Bocchia, MD29*, Monia Lunghi30*, Elisabetta Todisco31*, Paola Fazi3*, Alessandro Rambaldi32 and Robin Foà, MD4*

1Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy
2Azienda Ulss3 Serenissima,Hematology Unit, Ospedale dell'Angelo, Venezia, Italy
3GIMEMA Foundation, Rome, Italy
4Department of Translational and Precision Medicine, Division of Hematology, Sapienza University, Rome, Italy
5ASST Spedali Civili, Brescia, Department of Hematology, Brescia, Italy
6UO di Ematologia - Catania, Catania, Italy
7Department of Hematology and Oncology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
8U.O.C. Ematologia, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy
9ASO S. Croce e Carle, Cuneo, Italy
10Department of Medicine and Surgery, Division of Hematology and Clinical Immunology, University of Perugia, Perugia, Italy
11Department of Hematology, Ospedale Civile Spirito Santo, Pescara, Pescara, Italy
12UOC Ematologia e Trapianto Cellule Staminali Emopoietiche, Fondazione Policlinico Universitario A. Gemelli IRCCS Roma, Rome, Italy
13SC Ematologia 2, AOU Città della Salute e della Scienza, Turin, Italy
14Hematology Unit and Chair, Department of Medical and Surgical Sciences, Azienda Ospedaliera Universitaria di Modena, University of Modena and Reggio Emilia, Modena, Italy
15ASL DI PIACENZA, OSPEDALE "GUGLIELMO DA SALICETO", Piacenza, Italy
16Ematologia, Istituto Tumori Giovanni Paolo II- Bari, Bari, Italy
17Department of Medicine and Surgery, University of Salerno, University of Salerno, Baronissi, Salerno, Italy
18Hematology Unit, Hematology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
19ASSL NUORO, PRESIDIO OSPEDALIERO SAN FRANCESCO, Nuoro, Italy
20AO OSPEDALI RIUNITI MARCHE NORD - OSPEDALE SAN SALVATORE, Pesaro, Italy
21Department of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona, Verona, Italy
22Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
23Department of Medicine, Hematology and Clinical Immunology Unit, University of Padova, Padova, Italy
24ASL Salerno - Presidio Ospedaliero Tortora Pagani, Pagani, Italy
25Azienda Sanitaria dell'Alto Adige, Bolzano, ITA
26Hematology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
27Hematology and Bone Marrow Transplant, Unit San Raffaele Scientific Institute, Milano, Milano, Italy
28Division of Hematology, Azienda Ospedaliera SS Arrigo E Biagio E Cesare Arrigo, Alessandria, ITA
29Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy
30Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
31Hematology and Stem Cell Transplantation Division, European Institute of Oncology, Milan, Italy
32Hematology and Bone Marrow Transplant Unit, ASST Papa Giovanni XXIII, Bergamo, Italy

Introduction. The outcome of adult patients with newly diagnosed Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL) has markedly improved in recent years, first due to the introduction of tyrosine kinase inhibitors (TKI) and more recently with the combination with immunotherapy (blinatumomab). In the previous GIMEMA LAL2116 trial, we showed the effectiveness of a chemo-free approach based on dasatinib followed by blinatumomab (Foà et al, NEJM 2020), with long-term (median follow-up 53 months) overall survival (OS) and disease-free survival (DFS) of 80.7% and 75.8%, respectively (Foà et al, JCO 2023). Nine relapses were recorded. To improve the results obtained and reduce relapses, in the experimental arm of the current phase III trial ALL2820 trial, ponatinib was used in place of dasatinib. The trial is expected to complete enrolment in 2024. Here we report the updated results in terms of complete hematologic remission (CHR), measurable residual disease (MRD) and OS, as well as toxicity profile of the experimental arm.

Methods. Between September 2021 and July 2024, 200 newly diagnosed adult Ph+ ALL patients were enrolled. One hundred thirty three patients were randomized to the experimental arm that contemplated a steroid pre-phase followed by a 70-day induction with ponatinib at 45 mg or 30 mg according to age (less or more than 65 years) followed by at least 2 cycles (maximum 5) of blinatumomab. Median age was 57 years (20-87), 27% of patients being >65 years; 52% were female, the white blood count was 11x109/l (1-244); the p190 protein was detected in 70% of cases and 30% carried the p210 or 190/p210 protein.

Results. By the end of the induction, 110 patients (95%) achieved a CHR; 4 (3%) died in induction (pneumonia in 2, ileus paralyticus in 1 and death of unknown causes in 1) and 2 (1.5%) went off-study due to cardiac toxicity, while being in CHR. The remaining 17 cases are still receiving induction. A MRD response (complete molecular response plus positive non quantifiable) was recorded in 45% of cases.

By the end of the second cycle of blinatumomab, 93 of the 95 evaluable patients (98%) were in CHR, 1 withdraw consent due to non-compliance and 1 experienced a hematologic relapse. MRD response raised to 73%.

Overall, 52 grade >3 adverse events due to ponatinib were recorded, the most frequent being hepatic (20), hematologic (12) and pancreatic (8); cardiac toxicities were relatively rare, with only 5 events; finally, 5 infectious episodes (2 sepsis) and 2 cutaneous events were also reported.

The combination of ponatinib with blinatumomab led to 18 grade >3 adverse events: 8 were hematologic (5 in a single case), 4 were infections, 2 cytokine release syndromes and 2 neurologic related events were documented, as well as 2 gastrointestinal events.

Forty percent of patients required a dose reduction and/or a transient interruption: the most frequent toxicities were represented by grade 3 transaminitis in 10 patients and grade 2 in 6; an increase in pancreatic enzymes was observed in 6 cases (4 grade 3 and 2 grade 2); a cardiac toxicity was recorded in 6 patients, leading to a permanent discontinuation only in 2 cases. Other adverse events requiring a dose reduction were cutaneous rush, pharyngeal abscess, COVID-19 infection, and hematologic toxicity, documented in 1 case each. There was not a significant enrichment of toxicity leading to dose reduction/transient interruption in elderly.

So far, only 3 relapses (3%) have been recorded: 1 was BCR::ABL1-negative, suggesting the presence at diagnosis of a non Ph+ subclone, and 1 was recorded in a case who discontinued treatment for cardiovascular toxicity. Transplant allocation was based on an IKZF1plus profile at presentation and MRD persistence; so far, only 12% of patients have been allografted. At a median follow-up of 6.4 months (range 0.1-32.3), the estimated 18-month OS is 91.6%.

Conclusions. The intermediate analysis of the GIMEMA ALL2820 trial shows the feasibility and efficacy of a frontline chemo-free induction/consolidation approach with ponatinib and blinatumomab for Ph+ ALL adults of all ages. The combination was overall well tolerated, with very few treatment discontinuations, also in the elderly, suggesting that a ponatinib dose adjustment according to age may prevent severe toxicities. Lastly, with the biology-driven transplant allocation only 12% of patients have been transplanted so far.

Disclosures: Chiaretti: Abbvie: Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees. Borlenghi: Amgen: Other: Travel Grant; Abbvie: Consultancy; BMS: Consultancy; Incyte: Other: Travel Grant. Bonifacio: BMS: Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria. Fracchiolla: Abbvie: Speakers Bureau; Jazz: Speakers Bureau; Amgen: Speakers Bureau; Pfizer: Speakers Bureau. Zappasodi: pfizer: Consultancy, Honoraria; Abbvie: Honoraria; astellas: Honoraria; Amgen: Honoraria. Bocchia: Novartis: Honoraria, Other: travel grant; Incyte: Honoraria, Other: travel grant; Abbvie: Honoraria, Other: travel grants. Rambaldi: Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Astellas: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Jazz: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Incyte: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Kite-Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Omeros: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau.

Previous Abstract | Next Abstract >>
*signifies non-member of ASH